🔗 Share this article

While America undertakes unprecedented revisions to its immunization guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccines throughout the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Program

Agency leaders had intended to unveil major revisions to the pediatric vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a substantial departure that would place the US out of step with much of the global community with insufficient data for improved outcomes. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to lead the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for ending some childhood shot schedules in the US so as to align more similar to Denmark, a nation with universal health coverage and a citizenry about the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Qualifications

Dr. Høeg has little discernible track record in drug development, approval processes or leadership, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She is not an expert in industry regulation.”

Former directors of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, commented Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who headed CBER have had.”

CDER has an vast range of responsibilities at the FDA, she stated.

“The public just focuses on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There’s a biosimilars division, OTC medication office and other areas, and each of these have to be looked after,” Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major management aspect to the job, which supervises in excess of 5,000 employees. “It is a enormous leadership role, if you execute it properly,” she concluded.

Agency Reaction and Controversial Policies

Regarding questions about Dr. Høeg's credentials and whether this assignment signifies more teamwork among agency officials on vaccines, a press secretary stated that the “inquiries are based on flawed premises”.

“This background matches the functions of her job,” the official explained, pointing to the time Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the agency head's controversial priority voucher program, a disputed one-day therapy clearance system that allegedly concerned her preceding directors. “By what process are these medications being chosen for this fast-track system? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he said, “the agency appears to be shifting towards more relaxed regulations of pharmaceuticals, except for vaccines.”

Documented Track Record on Vaccines

Regarding immunizations, Høeg has a more established, if concerning, history, some experts observe. She released a analysis using non-validated volunteer-provided data to determine the incidence of myocarditis after Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the new government included changing guidelines for new vaccines and discontinuing “unnecessary” immunizations, she said post-election on a online show. At the FDA, Høeg has reportedly proposed excluding adolescent males from receiving Covid vaccines.

“She’s an all-around ideologue who starts off with her conclusions and reverse-engineers to retrofit the data in a highly disingenuous, untruthful way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of other dissenters, {like|